Abstract:

Ovarian cancer poses a significant threat to women′s health worldwide due to its high mortality rate, which is mainly attributed to the difficulties in early diagnosis and chemotherapy resistance. As an emerging technology, microfluidic technology shows certain potential in ovarian cancer diagnosis and treatment, thanks to its advantages such as high sensitivity, low sample/reagents consumption, rapid response, and cost-effectiveness. In the field of diagnosis, microfluidic technology breaks through the limitations of single-biomarker detection by jointly detecting multiple biomarkers, enabling high-sensitivity and rapid screening. Moreover, it significantly improves the reliability of early diagnosis of ovarian cancer through liquid biopsy, such as screening exosome biomarkers and efficiently identifying circulating tumor cells. In terms of treatment, microfluidic technology reveals drug-resistance mechanisms by simulating the tumor microenvironment, develops targeted delivery systems to enhance drug sensitivity, and precisely constructs controllable-release nanocarriers to optimize drug efficacy and safety. With the continuous advancement of microfluidic technology, it is expected to bring more precise and effective diagnostic and treatment options for patients.

Key words: Ovarian neoplasms, Lab-on-a-chip devices, Biomarkers, tumor, Liquid biopsy, Drug screening assays, antitumor, Precision medicine, Microfluidic technology